Foghorn Therapeutics (FHTX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.85, -2.12% vs the prior close of $1.89.
- Volume 981.23K shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
FHTX dips 2.1% to $1.85. Closed at $1.85, -2.12% vs the prior close of $1.89. Day range $1.82–$1.90, opened at $1.90.
FHTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — FHTX dips 2.1% to $1.85
- Closed at $1.85, -2.12% vs the prior close of $1.89. Day range $1.82–$1.90, opened at $1.90.
- Volume was 981.23K shares, 1.2x its 50-day average of 793.18K.
- Price is -59.0% vs its 50-day average ($4.51) and -62.1% vs its 200-day average ($4.88).
- 52-week range $1.79–$7.61; today's close sits at 1% of that range, 75.7% below the 52-week high.
Oct 15, 2026 — FHTX rises 2.2% to $1.89
- Closed at $1.89, +2.16% vs the prior close of $1.85. Day range $1.82–$1.91, opened at $1.87.
- Volume was 347.10K shares, 0.4x its 50-day average of 789.42K — lighter than usual.
- Price is -58.8% vs its 50-day average ($4.59) and -61.4% vs its 200-day average ($4.90).
- 52-week range $1.79–$7.61; today's close sits at 2% of that range, 75.2% below the 52-week high.
Oct 14, 2026 — FHTX ends flat (+0.0%) to $1.85, 3 down days in a row
- Closed at $1.85, +0.00% vs the prior close of $1.85. Day range $1.80–$1.89, opened at $1.85.
- Volume was 1.07M shares, 1.4x its 50-day average of 771.19K.
- Price is -60.2% vs its 50-day average ($4.65) and -62.4% vs its 200-day average ($4.92).
- 52-week range $1.79–$7.61; today's close sits at 1% of that range, 75.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — FHTX slides 5.1% to $1.85, a 52-week low
- Closed at $1.85, -5.13% vs the prior close of $1.95. Day range $1.84–$1.95, opened at $1.95.
- Volume was 851.10K shares, 1.1x its 50-day average of 758.46K.
- Price is -60.7% vs its 50-day average ($4.71) and -62.5% vs its 200-day average ($4.94).
- 52-week range $1.79–$7.61; today's close sits at 1% of that range, 75.7% below the 52-week high.
Oct 12, 2026 — FHTX dips 2.5% to $1.95, a 52-week low
- Closed at $1.95, -2.50% vs the prior close of $2.00. Day range $1.94–$2.00, opened at $1.98.
- Volume was 586.30K shares, 0.8x its 50-day average of 749.88K.
- Price is -59.1% vs its 50-day average ($4.76) and -60.6% vs its 200-day average ($4.95).
- 52-week range $1.79–$7.61; today's close sits at 3% of that range, 74.4% below the 52-week high.
Oct 9, 2026 — FHTX rises 0.5% to $2.00
- Closed at $2.00, +0.50% vs the prior close of $1.99. Day range $1.95–$2.08, opened at $1.96.
- Volume was 646.70K shares, 0.9x its 50-day average of 740.42K.
- Price is -58.5% vs its 50-day average ($4.81) and -59.8% vs its 200-day average ($4.97).
- 52-week range $1.79–$7.61; today's close sits at 4% of that range, 73.7% below the 52-week high.
Oct 8, 2026 — FHTX slides 4.8% to $1.99
- Closed at $1.99, -4.78% vs the prior close of $2.09. Day range $1.88–$2.14, opened at $2.05.
- Volume was 1.22M shares, 1.7x its 50-day average of 720.04K.
- Price is -59.1% vs its 50-day average ($4.87) and -60.1% vs its 200-day average ($4.99).
- 52-week range $1.79–$7.61; today's close sits at 3% of that range, 73.9% below the 52-week high.
Oct 7, 2026 — FHTX jumps 6.1% to $2.09
- Closed at $2.09, +6.09% vs the prior close of $1.97. Day range $1.91–$2.15, opened at $1.92.
- Volume was 914.80K shares, 1.3x its 50-day average of 704.93K.
- Price is -57.6% vs its 50-day average ($4.92) and -58.2% vs its 200-day average ($5.01).
- 52-week range $1.79–$7.61; today's close sits at 5% of that range, 72.5% below the 52-week high.
Oct 6, 2026 — FHTX dips 1.5% to $1.97, a 52-week low, 4 down days in a row
- Closed at $1.97, -1.50% vs the prior close of $2.00. Day range $1.84–$2.02, opened at $2.00.
- Volume was 984.50K shares, 1.4x its 50-day average of 688.43K.
- Price is -60.5% vs its 50-day average ($4.99) and -60.8% vs its 200-day average ($5.02).
- 52-week range $1.79–$7.61; today's close sits at 3% of that range, 74.1% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — FHTX dips 1.0% to $2.00, a 52-week low, 3 down days in a row
- Closed at $2.00, -0.99% vs the prior close of $2.02. Day range $1.98–$2.12, opened at $2.03.
- Volume was 988.00K shares, 1.5x its 50-day average of 671.11K.
- Price is -60.4% vs its 50-day average ($5.05) and -60.3% vs its 200-day average ($5.03).
- 52-week range $1.79–$7.61; today's close sits at 4% of that range, 73.7% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — FHTX slides 30.8% to $2.02, a 52-week low on 4.1x normal volume
- Closed at $2.02, -30.82% vs the prior close of $2.92. Day range $1.99–$2.91, opened at $2.91.
- Volume was 2.55M shares, 4.1x its 50-day average of 622.91K — unusually heavy trading.
- Price is -60.4% vs its 50-day average ($5.11) and -60.0% vs its 200-day average ($5.05).
- 52-week range $1.79–$7.61; today's close sits at 4% of that range, 73.5% below the 52-week high.
FHTX latest news & SEC filings
Every SEC filing by or about FHTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Oct 5, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.05 — Costs tied to exiting activities / restructuring.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $16.07M (prior year $7.56M) (+112.7% vs Jun 30, 2025)
- Net income: -$7.19M (prior year -$17.94M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.10 (prior year -$0.28) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade FHTX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 11, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.88% (largest 30.8%). That is a volatile stock.
- Liquidity: about 1.45M shares (≈$2.68M) trade per day on average.
- 52-week position: $1.85 vs a range of $1.79–$7.61 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 1, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 59.39M shares outstanding (Jul 31, 2026), +5.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
FHTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.90 | 1.90 | 1.82 | 1.85 | 981.23K |
| Oct 15, 2026 | 1.87 | 1.91 | 1.82 | 1.89 | 347.10K |
| Oct 14, 2026 | 1.85 | 1.89 | 1.80 | 1.85 | 1.07M |
| Oct 13, 2026 | 1.95 | 1.95 | 1.84 | 1.85 | 851.10K |
| Oct 12, 2026 | 1.98 | 2.00 | 1.94 | 1.95 | 586.30K |
| Oct 9, 2026 | 1.96 | 2.08 | 1.95 | 2.00 | 646.70K |
| Oct 8, 2026 | 2.05 | 2.14 | 1.88 | 1.99 | 1.22M |
| Oct 7, 2026 | 1.92 | 2.15 | 1.91 | 2.09 | 914.80K |
| Oct 6, 2026 | 2.00 | 2.02 | 1.84 | 1.97 | 984.50K |
| Oct 5, 2026 | 2.03 | 2.12 | 1.98 | 2.00 | 988.00K |
| Oct 2, 2026 | 2.91 | 2.91 | 1.99 | 2.02 | 2.55M |
| Oct 1, 2026 | 2.08 | 3.21 | 1.79 | 2.92 | 13.37M |
| Sep 30, 2026 | 3.55 | 3.60 | 3.50 | 3.57 | 420.00K |
| Sep 29, 2026 | 3.53 | 3.58 | 3.46 | 3.52 | 376.20K |
| Sep 28, 2026 | 3.49 | 3.62 | 3.40 | 3.52 | 337.20K |
| Sep 25, 2026 | 3.61 | 3.66 | 3.46 | 3.50 | 525.40K |
| Sep 24, 2026 | 3.83 | 3.85 | 3.55 | 3.60 | 517.90K |
| Sep 23, 2026 | 4.12 | 4.21 | 3.85 | 3.87 | 1.80M |
| Sep 22, 2026 | 4.21 | 4.32 | 4.15 | 4.24 | 328.90K |
| Sep 21, 2026 | 4.16 | 4.19 | 4.07 | 4.15 | 188.40K |
About Foghorn Therapeutics
Foghorn Therapeutics (FHTX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1822462.
FHTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Noubar Afeyan | Director | Jan 15, 2026 |
| Scott Biller | Director | Jun 25, 2026 |
| Douglas G. Cole | Director | Jun 25, 2026 |
| Stuart Duty | Director | Jun 25, 2026 |
| Pioneering Fund Vii General Partner Llc Flagship | Director | Jan 15, 2026 |
| Pioneering Fund Vii, L.P. Flagship | Director | Jan 15, 2026 |
| Pioneering Special Opportunities Fund Ii General Partner Llc Flagship | Director | Jan 15, 2026 |
| Pioneering Special Opportunities Fund Ii, L.P. Flagship | Director | Jan 15, 2026 |
| Pioneering, Llc Flagship | Director | Jan 15, 2026 |
| Ventures Fund V General Partner Llc Flagship | Director | Jan 15, 2026 |
| Ventures Fund V, L.P. Flagship | Director | Jan 15, 2026 |
| Ventures Opportunities Fund I General Partner Llc Flagship | Director | Jan 15, 2026 |
| Ventures Opportunities Fund I, L.P. Flagship | Director | Jan 15, 2026 |
| Simba Gill | Director | Jun 25, 2026 |
| Adrian Gottschalk | Chief Executive Officer | Apr 13, 2026 |
| Neil Gallagher | Director | Jun 25, 2026 |
| Thomas J. Jr. Lynch | Director | Jun 25, 2026 |
| Michael Mendelsohn | Director | Jun 25, 2026 |
| B Lynne Parshall | Director | Jun 25, 2026 |
| Ian F Smith | Director | Jun 25, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Steven F. Bellon | Chief Scientific Officer | Feb 2, 2026 |
| Alfonso Quintas Cardama | Chief Medical Officer | Feb 2, 2026 |
| Carlos Costa | Chief People Officer | Feb 2, 2026 |
| Adrian Gottschalk | Chief Executive Officer | Apr 13, 2026 |
| Kristian Humer | Chief Financial Officer | Nov 17, 2025 |
| Michael Lacascia | Chief Legal Officer | Feb 2, 2026 |
| Ryan D Maynard | Chief Financial Officer | Feb 24, 2026 |
| Anna Rivkin | Chief Business Officer | Feb 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
FHTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $30.91M | $-74.28M | -1.18 | $-86.10M |
| Dec 31, 2024 | $22.60M | $-86.62M | -1.58 | $-100.41M |
| Dec 31, 2023 | $34.16M | $-98.43M | -2.34 | $-118.11M |
| Dec 31, 2022 | $19.23M | $-108.88M | -2.62 | $193.61M |
| Dec 31, 2021 | $1.32M | $-101.32M | -2.73 | $-50.25M |
Latest balance sheet: total assets $203.39M, total liabilities $284.43M, cash $68.08M (as of Jun 30, 2026).
FHTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $5.57 |
| May 7, 2026 | 8-K Item 2.02 (results) | $4.20 |
| Mar 11, 2026 | 8-K Item 2.02 (results) | $5.65 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $6.38 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $4.00 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $5.00 |
| May 14, 2025 | 8-K Item 2.02 (results) | $4.11 |
| Mar 6, 2025 | 8-K Item 2.02 (results) | $4.50 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $4.37 |
| Nov 4, 2024 | 8-K Item 2.02 (results) | $8.24 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 6, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on FHTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.